Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Stephen Harvey Zinner, M.D.

Concepts

This page shows the publications Stephen Zinner has written about Fluoroquinolones.
Connection Strength

3.411
  1. Profile of a Novel Anionic Fluoroquinolone-Delafloxacin. Clin Infect Dis. 2019 04 08; 68(Suppl 3):S213-S222.
    View in: PubMed
    Score: 0.682
  2. Antistaphylococcal effect related to the area under the curve/MIC ratio in an in vitro dynamic model: predicted breakpoints versus clinically achievable values for seven fluoroquinolones. Antimicrob Agents Chemother. 2005 Jul; 49(7):2642-7.
    View in: PubMed
    Score: 0.263
  3. Fluoroquinolone prophylaxis in patients with neutropenia. Clin Infect Dis. 2005 Apr 15; 40(8):1094-5.
    View in: PubMed
    Score: 0.257
  4. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model. Int J Antimicrob Agents. 2004 Aug; 24(2):173-7.
    View in: PubMed
    Score: 0.247
  5. The pharmacodynamics of gatifloxacin and ciprofloxacin for pneumococci in an in vitro dynamic model: prediction of equiefficient doses. J Antimicrob Chemother. 2001 Dec; 48(6):821-6.
    View in: PubMed
    Score: 0.205
  6. Comparative anti-staphylococcal effects of gemifloxacin and trovafloxacin in an in vitro dynamic model in terms of AUC/MIC and dose relationships. Diagn Microbiol Infect Dis. 2001 Aug; 40(4):167-71.
    View in: PubMed
    Score: 0.200
  7. Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model. J Antimicrob Chemother. 1999 Apr; 43(4):483-90.
    View in: PubMed
    Score: 0.170
  8. A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities. Antimicrob Agents Chemother. 1998 Nov; 42(11):2841-7.
    View in: PubMed
    Score: 0.165
  9. Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept. Antimicrob Agents Chemother. 1998 Mar; 42(3):659-65.
    View in: PubMed
    Score: 0.158
  10. Activity of trovafloxacin (with or without ampicillin-sulbactam) against enterococci in an in vitro dynamic model of infection. Antimicrob Agents Chemother. 1998 Jan; 42(1):72-7.
    View in: PubMed
    Score: 0.156
  11. Enrichment of fluoroquinolone-resistant Staphylococcus aureus: oscillating ciprofloxacin concentrations simulated at the upper and lower portions of the mutant selection window. Antimicrob Agents Chemother. 2008 Jun; 52(6):1924-8.
    View in: PubMed
    Score: 0.079
  12. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. Int J Antimicrob Agents. 2005 May; 25(5):409-13.
    View in: PubMed
    Score: 0.065
  13. ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model. J Antimicrob Chemother. 2004 Jul; 54(1):178-86.
    View in: PubMed
    Score: 0.061
  14. Prevention of the selection of resistant Staphylococcus aureus by moxifloxacin plus doxycycline in an in vitro dynamic model: an additive effect of the combination. Int J Antimicrob Agents. 2004 May; 23(5):451-6.
    View in: PubMed
    Score: 0.061
  15. Concentration-dependent changes in the susceptibility and killing of Staphylococcus aureus in an in vitro dynamic model that simulates normal and impaired gatifloxacin elimination. Int J Antimicrob Agents. 2004 Jan; 23(1):60-6.
    View in: PubMed
    Score: 0.059
  16. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing. J Antimicrob Chemother. 2003 Oct; 52(4):616-22.
    View in: PubMed
    Score: 0.058
  17. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother. 2003 May; 47(5):1604-13.
    View in: PubMed
    Score: 0.056
  18. AUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin and levofloxacin. J Antimicrob Chemother. 2002 Oct; 50(4):533-9.
    View in: PubMed
    Score: 0.054
  19. Species-independent pharmacodynamics of gemifloxacin and ciprofloxacin with Haemophilus influenzae and Moraxella catarrhalis in an in vitro dynamic model. Int J Antimicrob Agents. 2002 Sep; 20(3):201-5.
    View in: PubMed
    Score: 0.054
  20. Bacterial strain-independent AUC/MIC and strain-specific dose-response relationships reflecting comparative fluoroquinolone anti-pseudomonal pharmacodynamics in an in vitro dynamic model. Int J Antimicrob Agents. 2002 Jul; 20(1):44-9.
    View in: PubMed
    Score: 0.053
  21. Relationships of the area under the curve/MIC ratio to different integral endpoints of the antimicrobial effect: gemifloxacin pharmacodynamics in an in vitro dynamic model. Antimicrob Agents Chemother. 2001 Mar; 45(3):927-31.
    View in: PubMed
    Score: 0.049
  22. Gemifloxacin and ciprofloxacin pharmacodynamics in an in-vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and doses. Int J Antimicrob Agents. 2000 Dec; 16(4):407-14.
    View in: PubMed
    Score: 0.048
  23. Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses. J Antimicrob Chemother. 2000 Nov; 46(5):725-32.
    View in: PubMed
    Score: 0.048
  24. Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: prediction of equiefficient doses and the breakpoints of the area under the curve/MIC ratio. Antimicrob Agents Chemother. 2000 Apr; 44(4):879-84.
    View in: PubMed
    Score: 0.046
  25. In vitro dynamic model for determining the comparative pharmacology of fluoroquinolones. Am J Health Syst Pharm. 1999 Nov 15; 56(22 Suppl 3):S12-5.
    View in: PubMed
    Score: 0.044
  26. Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model. Antimicrob Agents Chemother. 1999 Mar; 43(3):498-502.
    View in: PubMed
    Score: 0.042
  27. In vitro antimicrobial activity of moxifloxacin against bacterial strains isolated from blood of neutropenic cancer patients. Eur J Clin Microbiol Infect Dis. 2006 Aug; 25(8):537-40.
    View in: PubMed
    Score: 0.018
  28. Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters. Chemotherapy. 2002; 48(6):275-9.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.